NASDAQ:ADAP Adaptimmune Therapeutics (ADAP) Stock Price, News & Analysis $1.09 -0.02 (-1.80%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$1.08▼$1.1550-Day Range$0.98▼$1.3952-Week Range$0.42▼$2.05Volume1.00 million shsAverage Volume1.79 million shsMarket Capitalization$269.04 millionP/E RatioN/ADividend YieldN/APrice Target$3.38 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Adaptimmune Therapeutics alerts: Email Address Adaptimmune Therapeutics MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside210.4% Upside$3.38 Price TargetShort InterestHealthy2.89% of Shares Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingSelling Shares$22,814 Sold Last QuarterProj. Earnings GrowthDecreasingFrom ($0.23) to ($0.63) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.08 out of 5 starsMedical Sector746th out of 910 stocksBiological Products, Except Diagnostic Industry124th out of 155 stocks 3.5 Analyst's Opinion Consensus RatingAdaptimmune Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageAdaptimmune Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Adaptimmune Therapeutics' stock forecast and price target. Previous Next 3.0 Short Interest Percentage of Shares Shorted2.89% of the outstanding shares of Adaptimmune Therapeutics have been sold short.Short Interest Ratio / Days to CoverAdaptimmune Therapeutics has a short interest ratio ("days to cover") of 3.3, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous month Previous Next 0.0 Dividend Strength Dividend YieldAdaptimmune Therapeutics does not currently pay a dividend.Dividend GrowthAdaptimmune Therapeutics does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for ADAP. Previous Next 0.0 News and Social Media Coverage Search InterestOnly 10 people have searched for ADAP on MarketBeat in the last 30 days. This is a decrease of 0% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Adaptimmune Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -83% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Adaptimmune Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $22,814.00 in company stock.Percentage Held by Insiders12.44% of the stock of Adaptimmune Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 31.37% of the stock of Adaptimmune Therapeutics is held by institutions.Read more about Adaptimmune Therapeutics' insider trading history. Previous Next 0.0 Earnings and Valuation Earnings GrowthEarnings for Adaptimmune Therapeutics are expected to decrease in the coming year, from ($0.23) to ($0.63) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Adaptimmune Therapeutics is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adaptimmune Therapeutics is -1.47, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdaptimmune Therapeutics has a P/B Ratio of 2.87. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.Read more about Adaptimmune Therapeutics' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad True Gold RepublicChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a population of over 1.4 BILLION is “buying gold like there’s no tomorrow,” according to The New York Times. China, a rising global economic threat, aims to reduce its dependence on the US dollar… . Click here now to get your free 'De-Dollarization' Guide. About Adaptimmune Therapeutics Stock (NASDAQ:ADAP)Adaptimmune Therapeutics plc, a clinical-stage biopharmaceutical company, provides novel cell therapies primarily to cancer patients in the United States and the United Kingdom. It develops SPEARHEAD-1 that is in phase II clinical trials with ADP-A2M4 for synovial sarcoma; SURPASS-3 that is in phase II clinical trial with ADP-A2M4CD8 for people with platinum resistant ovarian cancer; and SURPASS that is in phase I clinical trials in patients with head and neck, and urothelial cancers. The company has strategic collaboration and license agreement with Genentech, Inc. and F. Hoffman-La Roche Ltd to develop personalized allogeneic and allogeneic T-cell therapies; research, collaboration, and license agreement with Universal Cells, Inc.; third-party collaborations with Noile-Immune and Alpine Immune Sciences; and strategic alliance agreement with the MD Anderson Cancer Center. Adaptimmune Therapeutics plc was founded in 2008 and is headquartered in Abingdon, the United Kingdom.Read More ADAP Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart ADAP Stock News HeadlinesAugust 29, 2024 | finanznachrichten.deAdaptimmune Therapeutics PLC: Adaptimmune to Participate in Two Bank Conferences this SeptemberAugust 29, 2024 | americanbankingnews.comCritical Analysis: Protalix BioTherapeutics (NYSE:PLX) versus Adaptimmune Therapeutics (NASDAQ:ADAP)September 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 15, 2024 | markets.businessinsider.comHold Rating on Adaptimmune Amid Commercialization and Financial UncertaintiesAugust 15, 2024 | finance.yahoo.comAdaptimmune Therapeutics (NASDAQ:ADAP) investors are sitting on a loss of 74% if they invested three years agoAugust 13, 2024 | markets.businessinsider.comBuy Rating Affirmed for Adaptimmune Therapeutics Amidst Promising Product Launch and Strong PipelineAugust 13, 2024 | msn.comAdaptimmune Therapeutics plc (NASDAQ:ADAP) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | markets.businessinsider.comBuy Rating Justified by Adaptimmune’s Promising Financials and Strong Product Launch ProspectsSeptember 7, 2024 | Golden Crest (Ad)Biden's Successor: The Radical Threat to YOUR Savings!Kamala Harris isn't just playing politics; she's a serious threat to your financial security. Kamala has a plan to take over your money and leave you with nothing. Higher taxes, government control, and a digital dollar to track every penny you spend. This isn't about convenience; it's about CONTROL.August 12, 2024 | seekingalpha.comAdaptimmune Therapeutics plc (ADAP) Q2 2024 Earnings Call TranscriptAugust 12, 2024 | markets.businessinsider.comADAP Stock Earnings: Adaptimmune Therapeutics Beats EPS, Beats Revenue for Q2 2024August 12, 2024 | finance.yahoo.comBP_CCB RP1911F (66756.HK)August 9, 2024 | finance.yahoo.comAdaptimmune leads in soft tissue sarcoma therapy with first TCR approvalAugust 8, 2024 | bizjournals.comSeed Therapeutics enters into collaboration deal valued at up to $1.5B with Japan-based EisaiAugust 7, 2024 | markets.businessinsider.comOutperform Rating Affirmed for Adaptimmune Following FDA Approval and Positive Market Outlook for TecelraAugust 5, 2024 | markets.businessinsider.comAnalysts’ Opinions Are Mixed on These Healthcare Stocks: Adaptimmune Therapeutics (ADAP), Lantheus (LNTH) and Vertex Pharmaceuticals (VRTX)August 2, 2024 | msn.comAdaptimmune granted FDA accelerated nod for lead assetAugust 2, 2024 | msn.comFDA Approves Adaptimmune Therapeutics' Engineered Cell Therapy As First For Solid Tumor And New Therapy For Rare Soft Tissue Cancer In Over A DecadeSee More Headlines Receive ADAP Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adaptimmune Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings8/12/2024Today9/07/2024Next Earnings (Estimated)11/13/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADAP CUSIPN/A CIK1621227 Webwww.adaptimmune.com Phone441235430000Fax44-12-3543-0001Employees490Year FoundedN/APrice Target and Rating Average Stock Price Target$3.38 High Stock Price Target$4.00 Low Stock Price Target$3.00 Potential Upside/Downside+210.4%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($0.74) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-113,870,000.00 Net Margins-51.25% Pretax Margin-50.49% Return on Equity-116.80% Return on Assets-25.02% Debt Debt-to-Equity Ratio0.26 Current Ratio3.09 Quick Ratio3.09 Sales & Book Value Annual Sales$141.46 million Price / Sales1.90 Cash FlowN/A Price / Cash FlowN/A Book Value$0.38 per share Price / Book2.87Miscellaneous Outstanding Shares246,825,000Free Float216,120,000Market Cap$269.04 million OptionableOptionable Beta2.31 12 Stocks Corporate Insiders are AbandoningIf a company's CEO, COO, and CFO were all selling shares of their stock, would you want to know?Get This Free Report Key ExecutivesMr. Adrian G. Rawcliffe (Age 52)CEO, Principal Accounting Officer & Director Comp: $693.64kMr. Gavin Hilary James Wood ACA (Age 54)BA (Hons), Chief Financial Officer Comp: $508.22kMr. William C. Bertrand Jr. (Age 59)Esq., J.D., Chief Operating Officer Comp: $573.8kDr. Elliot Norry B.A. (Age 60)M.D., Chief Medical Officer Comp: $549.05kMs. Cintia Piccina Pharm.D. (Age 50)Chief Commercial Officer Comp: $597.44kDr. Helen Katrina Tayton-Martin MBA (Age 57)Ph.D., Co-Founder & Chief Business & Strategy Officer Comp: $709.84kMs. Joanna Brewer Ph.D. (Age 48)Chief Scientific Officer Dr. Juli P. Miller Ph.D.VP of Corporate Affairs & Investor RelationsMs. Kerry SharpSenior VP & General CouncilDana LynchSenior Director of Corporate CommunicationsMore ExecutivesKey CompetitorsPrecigenNASDAQ:PGENFate TherapeuticsNASDAQ:FATECellectisNASDAQ:CLLSbluebird bioNASDAQ:BLUEAtara BiotherapeuticsNASDAQ:ATRAView All CompetitorsInsiders & InstitutionsLong Focus Capital Management LLCBought 1,662,184 shares on 8/15/2024Ownership: 5.002%Marshall Wace LLPSold 109,133 shares on 8/14/2024Ownership: 0.059%Renaissance Technologies LLCBought 394,566 shares on 8/9/2024Ownership: 0.724%Baillie Gifford & Co.Sold 722,672 shares on 7/25/2024Ownership: 6.138%Cintia PiccinaSold 24,531 sharesTotal: $22,813.83 ($0.93/share)View All Insider TransactionsView All Institutional Transactions ADAP Stock Analysis - Frequently Asked Questions How have ADAP shares performed this year? Adaptimmune Therapeutics' stock was trading at $0.7930 at the beginning of the year. Since then, ADAP shares have increased by 37.5% and is now trading at $1.09. View the best growth stocks for 2024 here. How were Adaptimmune Therapeutics' earnings last quarter? Adaptimmune Therapeutics plc (NASDAQ:ADAP) issued its earnings results on Monday, August, 12th. The biotechnology company reported $0.27 earnings per share (EPS) for the quarter. The biotechnology company earned $128.23 million during the quarter, compared to analyst estimates of $58 million. Adaptimmune Therapeutics had a negative net margin of 51.25% and a negative trailing twelve-month return on equity of 116.80%. What is Adrian Rawcliffe's approval rating as Adaptimmune Therapeutics' CEO? 6 employees have rated Adaptimmune Therapeutics Chief Executive Officer Adrian Rawcliffe on Glassdoor.com. Adrian Rawcliffe has an approval rating of 100% among the company's employees. This puts Adrian Rawcliffe in the top 10% of approval ratings compared to other CEOs of publicly-traded companies. When did Adaptimmune Therapeutics IPO? Adaptimmune Therapeutics (ADAP) raised $150 million in an initial public offering (IPO) on Wednesday, May 6th 2015. The company issued 9,400,000 shares at a price of $15.00-$17.00 per share. BofA Merrill Lynch, Cowen and Company and Leerink Partners acted as the underwriters for the IPO and Guggenheim Securities was co-manager. Who are Adaptimmune Therapeutics' major shareholders? Top institutional investors of Adaptimmune Therapeutics include Baillie Gifford & Co. (6.14%), Long Focus Capital Management LLC (5.00%), Renaissance Technologies LLC (0.72%) and Marshall Wace LLP (0.06%). Insiders that own company stock include Gavin Wood, Garry E Menzel, Cintia Piccina, Adrian Rawcliffe, William C Bertrand Jr, John Lunger and Elliot Norry. View institutional ownership trends. How do I buy shares of Adaptimmune Therapeutics? Shares of ADAP stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Adaptimmune Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adaptimmune Therapeutics investors own include Zynerba Pharmaceuticals (ZYNE), Xtrackers California Municipal Bond ETF (CA), Endologix (ELGX), Brainstorm Cell Therapeutics (BCLI), Second Sight Medical Products (EYES), Shopify (SHOP) and Micron Technology (MU). This page (NASDAQ:ADAP) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredBiden’s Capital Gains Tax to Devastate Savings!Don't let the corrupt elites dictate your future—ACT NOW! This guide is your first step towards financial inde...Golden Crest | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredChina Stockpiling Gold “Like No Tomorrow”For 18 consecutive months, China’s central bank has increased its gold reserve. The country, with a populat...True Gold Republic | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s weapon lurks in abandoned AmericaUnemployment is sky-high, wages are at record lows. Addiction has overwhelmed these once thriving coal towns. ...Porter & Company | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adaptimmune Therapeutics plc Please log in to your account or sign up in order to add this asset to your watchlist. Share Adaptimmune Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
